3,5-dichloro-4-isothiocyanato-pyridine | 1000709-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,5-dichloro-4-isothiocyanato-pyridine
• 英文别名: 3,5-Dichloro-4-isothiocyanatopyridine
• CAS: 1000709-58-9
• 化学式: C₆H₂Cl₂N₂S
• 分子量: 205.067
• InChiKey: UZRYPJAPINSGTR-UHFFFAOYSA-N

物化性质

• 沸点：
  306.3±42.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-dichloro-4-isothiocyanato-pyridine 在 水 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 sodium hydroxide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 24.0h， 生成 2-((3,5-dichloropyridin-4-yl)amino)-N-isopentyl-7-methyl-1H-benzofuro[4,5-d]-imidazole-5-carboxamide
  参考文献：
  名称：

  Discovery of furan and dihydrofuran-fused tricyclic benzo[ d ]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1

  摘要：

  This letter describes the synthesis and biological evaluation of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as novel mPGES-1 inhibitors, capable of inhibiting an increased PGE(2) production in the disease state. Structure-activity optimization afforded many potent mPGES-1 inhibitors having <50 nM potencies in the A549 cellular assay and adequate metabolic stability in liver microsomes. Lead compounds 8l and 8m demonstrated reasonable in vitro pharmacology and pharmacokinetic properties over other compounds. In particular, 8m revealed satisfactory oral pharmacokinetics and bioavailability in multiple species like rat, guinea pig, dog and cynomolgus monkey. In addition, the representative compound 8m showed in vivo efficacy by inhibiting LPS-induced thermal hyperalgesia with an ED50 of 14.3 mg/kg in guinea pig. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.10.062
• 作为产物：
  描述：

  4-氨基-3,5-二氯吡啶 、 硫光气 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3,5-dichloro-4-isothiocyanato-pyridine
  参考文献：
  名称：

  Tricyclic Compounds As mPGES-1 Inhibitors

  摘要：

  本发明涉及式(I)的三环化合物或其药用可接受的盐作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗各种疾病或病况引起的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。

  公开号：

  US20120108583A1

文献信息

• Thiazolopyrimidine modulators of TRPV1
  申请人：Branstetter Bryan James

  公开号：US20080004253A1

  公开（公告）日：2008-01-03

  Certain TRPV1-modulating thiazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  描述了某些调节TRPV1的噻唑吡咯啉化合物。这些化合物可以用于制备药物组合物和治疗由TRPV1活性介导的疾病状态、紊乱和病况的方法，如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病。
• 3H-Imidazo [4, 5-C] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20110275656A1

  公开（公告）日：2011-11-10

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供了化合物的公式(I)，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义如描述中所示，以及其药学上可接受的盐，这些化合物在治疗需要抑制MAPEG家族成员活性的疾病，特别是在治疗炎症和/或癌症方面非常有用。
• 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20120122930A1

  公开（公告）日：2012-05-17

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供公式（I）的化合物，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义如描述中所给，以及其药学上可接受的盐。这些化合物在治疗需要抑制MAPEG家族成员活性的疾病，特别是在治疗炎症和/或癌症方面非常有用。
• 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20120115902A1

  公开（公告）日：2012-05-10

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供了公式（I）的化合物，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义在说明中给出，并且其药学上可接受的盐，在希望和/或需要抑制MAPEG家族成员活性的疾病治疗中非常有用，特别是在炎症和/或癌症治疗中。
• Tricyclic compounds as mPGES-1 inhibitors
  申请人：Gharat Laxmikant A.

  公开号：US08519149B2

  公开（公告）日：2013-08-27

  The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本发明涉及公式(I)的三环化合物或其药学上可接受的盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或病况引起的疼痛和/或炎症方面非常有用，例如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。